Literature DB >> 27389554

Nuclear Survivin as a Prognostic Factor in Squamous-Cell Carcinoma of the Oral Cavity.

Andrea Santarelli1, Marco Mascitti, Corrado Rubini, Fabrizio Bambini, Giovanni Giannatempo, Lucio Lo Russo, Davide Sartini, Monica Emanuelli, Maurizio Procaccini, Lorenzo Lo Muzio.   

Abstract

Oral squamous-cell carcinoma (OSCC) and most human tumors are characterized by an imbalance of regulatory mechanisms controlling cell processes such as apoptosis. Survivin, a member of the inhibitor of apoptosis family, is overexpressed in most solid and hematological malignancies and correlates with a reduced overall survival rate. Thus, the aim of this study was to find a correlation between nuclear Survivin expression and clinicopathologic data and the prognosis in OSCC patients. A total of 152 OSCC samples were investigated by immunohistochemistry for nuclear Survivin expression. Then, Survivin was scored semiquantitatively using an immunoreactivity score (IRS), calculated by multiplying the percentage of positive cells with the staining intensity. Using a digital image analysis software, OSCC patients were stratified into 4 groups. Results showed that patients with a lower IRS score displayed better survival rates than patients with a higher IRS score, reaching statistical significance. As the expression of Survivin at the nuclear level seems to suggest a poor prognosis in OSCC patients, the evaluation of nuclear Survivin IRS may be a useful tool to identify patients with more aggressive and disseminated disease, influencing follow-up and therapeutic protocols.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27389554     DOI: 10.1097/PAI.0000000000000336

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  7 in total

Review 1.  Targeted Therapy Against the Cell of Origin in Cutaneous Squamous Cell Carcinoma.

Authors:  Stephen J Goldie; Ginevra Chincarini; Charbel Darido
Journal:  Int J Mol Sci       Date:  2019-05-05       Impact factor: 5.923

2.  Silencing of LncRNA SNHG16 Downregulates Cyclin D1 (CCND1) to Abrogate Malignant Phenotypes in Oral Squamous Cell Carcinoma (OSCC) Through Upregulating miR-17-5p.

Authors:  Qiuling Wang; Jingxin Han; Pu Xu; Xinchun Jian; Xieshan Huang; Deyu Liu
Journal:  Cancer Manag Res       Date:  2021-02-22       Impact factor: 3.989

Review 3.  Tumour-associated tissue eosinophilia (TATE) in oral squamous cell carcinoma: a comprehensive review.

Authors:  Marco Mascitti; Lucrezia Togni; Corrado Rubini; Giuseppe Troiano; Lorenzo Lo Muzio; Andrea Santarelli
Journal:  Histol Histopathol       Date:  2020-09-28       Impact factor: 2.303

Review 4.  Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.

Authors:  Andrea Santarelli; Marco Mascitti; Lucio Lo Russo; Davide Sartini; Giuseppe Troiano; Monica Emanuelli; Lorenzo Lo Muzio
Journal:  Int J Mol Sci       Date:  2018-03-24       Impact factor: 5.923

5.  Integrative Histologic and Bioinformatics Analysis of BIRC5/Survivin Expression in Oral Squamous Cell Carcinoma.

Authors:  Giuseppe Troiano; Agostino Guida; Gabriella Aquino; Gerardo Botti; Nunzia Simona Losito; Silvana Papagerakis; Maria Carmela Pedicillo; Franco Ionna; Francesco Longo; Monica Cantile; Antonio Pennella; Lucio Lo Russo; Giovanni Di Gioia; Maria Addolorata Mariggiò; Lorenzo Lo Muzio; Giuseppe Pannone
Journal:  Int J Mol Sci       Date:  2018-09-08       Impact factor: 5.923

6.  Selectin Binding Sites Are Involved in Cell Adhesive Properties of Head and Neck Squamous Cell Carcinoma.

Authors:  Ursula Valentiner; Jillian Knips; Ralph Pries; Till Clauditz; Adrian Münscher; Guido Sauter; Barbara Wollenberg; Udo Schumacher
Journal:  Cancers (Basel)       Date:  2019-10-28       Impact factor: 6.639

7.  Cordycepin Enhances Radiosensitivity in Oral Squamous Carcinoma Cells by Inducing Autophagy and Apoptosis Through Cell Cycle Arrest.

Authors:  Sheng-Yow Ho; Wun-Syuan Wu; Li-Ching Lin; Yuan-Hua Wu; Hui-Wen Chiu; Ya-Ling Yeh; Bu-Miin Huang; Ying-Jan Wang
Journal:  Int J Mol Sci       Date:  2019-10-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.